Prostate Cancer: Drugs
Commons · Question 12664 · Tabled 4 Nov 2024 · Department of Health and Social Care · Official record
Answered 12 Nov 2024
Question
Asked by Chris Ward
To ask the Secretary of State for Health and Social Care, what progress he has made on the development of a clinical policy relating to the use of abiraterone acetate as a first-line treatment for men with locally advanced high-risk prostate cancer; and w
Answer
Answered by Karin Smyth, 12 Nov 2024
NHS England has developed a policy proposal for abiraterone acetate and prednisolone to be used as a routine commissioning treatment option for high-risk, hormone sensitive, non-metastatic prostate cancer.In line with NHS England’s service development pro...